Slide 1: ou CAN | RUST
ou CAN | RUST
Slide 2: Topics Covered
Topics Covered 1. KPL – At a Glance 2. Business Model 3. Promotors Profile 4. Company History 5. Regulatory Approvals 6. Manufacturing Setup 7. Differentiated Capabilities 8. Key Markets By Sales 9. Future Plans 10.Financials 2
Slide 3: Disclaimer
DISCLAIMER Some of the statements made in this presentation are forward-looking statements and are based on the current beliefs, assumptions, expectations, estimates, objectives and projections of the directors and management of Kwality Pharmaceutical Limited about its business, the industry and mar
Slide 4: Kwality Pharma – At a Glance
K W A L I T Y P H A R M A – AT A G L A N C E 459.7 About Kwality Pharma Manufacturing Setup Total Revenues CAGR 8 Years = 21% • Catering to a wide range of Pharmaceutical Products Have 5 Formulation Units 263.6 5 Years = 13% 253.9 • Facilities based in Punjab & Himachal Pradesh • 3 Units in Amritsar
Slide 5: Business Model
BUSINESS MODEL Manufacturing • Each of the 5 manufacturing units have both injectables and OSD capabilities Plants • Manufacturing all type of products including complex molecules across all dosage forms including niche Biologics Product • Product portfolio of more than 3000+ formulations across 25+
Slide 6: Management Team Profile
MANAGEMENT TEAM PROFILE Mr. Ramesh Arora, Managing Director Ramesh Arora is a highly regarded figure in the pharmaceutical industry with an extensive experience. His visionary leadership has propelled Kwality Pharma Ltd to new heights, establishing it as a trusted name in the international market. T
Slide 7: Company's Timeline
C O M PA N Y ' S T I M E L I N E 2016 2017 2018 2019 • New Cephalosporin facility in HP • Started Marketing Office in Africa 2010 • Setup of new manufacturing in HP • PICs/GMP from Iran, Iraq & Tanzania • Upgraded Oncology facility Unit 3 in HP • New manufacturing with OSD and • Upgraded Generics Bl
Slide 8: Regulatory Approvals
R E G U L ATO RY A P P ROVA L S Five Manufacturing Units Across Two Locations Regulatory Approvals Already Received Jassur, HP Amritsar, PB Importance of Approvals –A testimony to KPL manufacturing capabilities • While exporting any pharmaceutical product, there are two types of approvals that may b
Slide 9: Manufacturing Setup
M A N U FA C T U R I N G S E T U P Amritsar Facility Biologics Admin Block / R&D Unit 6 Multiple Therapies Betalectam & Anti-infectives Utilities Multiple Therapies Unit1 Block A Unit1 Block W Unit-2 Cephalosporin Unit 4 Cytotoxic Unit 3 Admin Block 9
Slide 10: Manufacturing Setup
M A N U FA C T U R I N G S E T U P Locations Amritsar, Punjab Jassur, Himachal Pradesh Unit-1 Unit-2 Unit 5 Unit-6 Unit-3 Unit-4 Unit Names Block A & Block W1 *Proposed Establishment 2017 (Upgraded) FY25 / FY26 FY22 FY24 FY18 FY19 Year 2007 (First Built) Estimated Critical Care, Anaesthesia, Biologi
Slide 11: Differentiated Capabilities
D I F F E R E N T I AT E D C A PA B I L I T I E S Complex injectable drug products Key Technologies Involved Key Products Developed • Tissue targeting Developed complex oncology injectables with stability data of 24 months such as Liposomal Pegylated Injectables • Intracellular targeting Doxorubicin
Slide 12: Key Markets by Sales
KEY MARKETS BY SALES • Country: Brazil • Brazil is among the top 15 pharmaceuticals market by country in the world in value terms South and Central Africa Middle East Asia America Botswana Uganda Iran Egypt India Uzbekistan Colombia Costa Rica South • Region: Europe Kenya Iraq Algeria Sri Lanka Indo
Slide 13: Future Plans
FUTURE PLANS Strategic Goals 1. Leveraging the excellence in manufacturing to enter the global stringent regulated markets 2. Building long terms commercial partnerships both locally & globally 3. Focus on niche high margin portfolio of difficult to manufacture / register molecules 4. Increasing R&D
Slide 14: Key Financials
KEY FINANCIALS Income Statement FY19 FY20 FY21 FY22 FY23 Balance Sheet FY19 FY20 FY21 FY22 FY23 LIABILITIES 105.38 132.69 166.26 340.59 353.63 +Revenue from Ops (Gross) 166.29 139.30 262.01 456.19 251.03 +Shareholders’ funds 37.30 46.01 61.15 181.14 200.52 +Other Income 0.61 3.66 1.59 3.51 2.94 +Min
Slide 15: Thank You
THA NK YOU Kwality Pharmaceuticals Limited Registered Office Address: Village Nagkalan,Majitha Road, Amritsar-143601, Punjab, India Email: cs@kwalitypharma.com info@kwalitypharma.com 15